Hyperfine, Inc. announced that its next‑generation Swoop portable magnetic resonance imaging system and the accompanying Optive AI software have received CE and UKCA marks, clearing the products for sale in the European Economic Area and the United Kingdom as of April 9 2026.
The approvals follow the company’s earlier FDA clearance of the Swoop system in Q2 2025 and the FDA clearance of Optive AI in December 2025. The portable MRI market is projected to reach approximately USD 3.02 billion by 2030, with a CAGR of 15.8 %. Hyperfine’s ultra‑low‑field technology, particularly its new multi‑direction diffusion‑weighted imaging sequence, positions the company to capture a growing share of point‑of‑care brain imaging demand across Europe.
Hyperfine’s Q4 2025 earnings report, released on March 18 2026, showed revenue of $5.3 million, a 128 % year‑over‑year increase from $2.3 million in Q4 2024, and a gross margin of 50.9 %, up 1,530 basis points from the prior year. Management guided 2026 revenue to $20 million–$22 million and targeted a 55 % growth rate, reflecting confidence in the expanded European market and the scalability of its AI‑driven platform.
President and CEO Maria Sainz said, “We are proud to bring our most innovative technology to clinicians and patients in Europe and the UK and are thrilled to have achieved these approvals ahead of our internal expectations. This milestone is a testament to the exceptional execution of our product and regulatory teams and meaningfully advances a key pillar of Hyperfine’s 2026 international growth strategy.”
The CE and UKCA approvals enable Hyperfine to begin commercialization of the next‑generation Swoop system and Optive AI in Europe and the UK early in Q3 2026. The dual certification addresses both the post‑Brexit UK market and the broader European regulatory framework, positioning Hyperfine to compete more effectively against established MRI vendors and to accelerate adoption of its portable, AI‑enhanced brain imaging platform across hospitals, neurology practices, and other healthcare providers.
The regulatory milestone strengthens Hyperfine’s strategic trajectory, providing a clear path to broaden its customer base, increase revenue diversification, and reinforce its leadership position in the rapidly expanding portable MRI segment.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.